#BGBl. 2025 I Nr. 269Regulation on Increasing the Efficiency of the Federal Higher Authorities Responsible under the Medicinal Products Act
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This 2025 German regulation, officially published on 14 November 2025 in the Federal Law Gazette (BGBl. 2025 I Nr. 269), introduces measures to improve the operational efficiency of federal agencies responsible for implementing the Arzneimittelgesetz (AMG). The ordinance is led by the Federal Ministry of Health and focuses on streamlining administrative procedures, reducing processing times for approvals, and optimizing resource allocation within bodies such as the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institut. It aims to accelerate market access for medicinal products while maintaining safety standards through internal procedural reforms rather than changing substantive legal requirements.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Streamlining of administrative procedures for medicinal product approvals under the AMG
- Reduction of processing times for applications handled by BfArM and Paul-Ehrlich-Institut
- Optimization of internal resource allocation and workflow within responsible federal higher authorities
+ 2 more changes with Pro